PF-06755990 / Pfizer - LARVOL DELTA

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (clinicaltrials.gov) - P1; N=91; Terminated; Sponsor: Pfizer; Completed ➔ Terminated; Due to strategic evaluation of PF-06753512 (VBIR-1) within context of Pfizer's oncology portfolio, decision not based on any safety or regulatory concerns.

Clinical • Trial termination • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (clinicaltrials.gov) - P1; N=91; Completed; Sponsor: Pfizer; Active, not recruiting ➔ Completed; N=62 ➔ 91

Clinical • Enrollment change • Trial completion • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (clinicaltrials.gov) - P1; N=62; Active, not recruiting; Sponsor: Pfizer; Recruiting ➔ Active, not recruiting; N=160 ➔ 62

Clinical • Enrollment change • Enrollment closed • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (clinicaltrials.gov) - P1; N=160; Recruiting; Sponsor: Pfizer; N=91 ➔ 160; Trial completion date: Feb 2023 ➔ Feb 2021; Trial primary completion date: Feb 2023 ➔ Feb 2021

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (clinicaltrials.gov) - P1; N=91; Recruiting; Sponsor: Pfizer; N=160 ➔ 91

Clinical • Enrollment change • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (clinicaltrials.gov) - P1; N=133; Recruiting; Sponsor: Pfizer; Trial completion date: Sep 2021 ➔ Mar 2021

Trial completion date • Biosimilar • Prostate Cancer

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (clinicaltrials.gov) - P1; N=133; Recruiting; Sponsor: Pfizer; Trial completion date: Dec 2021 ➔ Feb 2023

Trial completion date

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (clinicaltrials.gov) - P1; N=133; Recruiting; Sponsor: Pfizer; Trial completion date: Oct 2022 ➔ Dec 2021; Trial primary completion date: Jun 2021 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date

A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR) (clinicaltrials.gov) - P1; N=133; Recruiting; Sponsor: Pfizer; Trial completion date: Mar 2021 ➔ Oct 2022; Trial primary completion date: Sep 2020 ➔ Jun 2021

Clinical • Trial completion date • Trial primary completion date